Avadel Pharmaceuticals PLC (AVDL)

NASDAQ
9.990
+0.650(+6.96%)
After Hours
8.500
-1.490(-14.915%)
- Real-time Data
  • Volume:
    2,969,196
  • Bid/Ask:
    8.300/8.500
  • Day's Range:
    9.850 - 10.400

AVDL Overview

Prev. Close
9.34
Day's Range
9.85-10.4
Revenue
-
Open
10.11
52 wk Range
4.95-10.8
EPS
-0.96
Volume
2,969,196
Market Cap
585.38M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
457,511
P/E Ratio
-
Beta
1.13
1-Year Change
82.97%
Shares Outstanding
58,596,238
Next Earnings Date
Nov 09, 2021
What is your sentiment on Avadel Pharmaceuticals PLC?
or
Market is currently closed. Voting is open during market hours.

Avadel Pharmaceuticals PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Buy
SummaryStrong SellStrong SellStrong BuyStrong BuyStrong Buy

Avadel Pharmaceuticals PLC Company Profile

Avadel Pharmaceuticals PLC Company Profile

Employees
32

Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

Read More
  • Brace yourselves
    0
    • Huge movements, what the **** is happening D: I like it
      0
      • "DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference, which is being held February 24th to 26th." https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-participate-fireside-chat-10th-annual-svb
        0
        • what do you think about this one?
          0
          • im in love with it
            0
          • gambling...
            0
        • This is a possible ten bagger if FDA aproves ft218
          0
          • that was news in Dec
            0
          • In december they submited to FDA for aproval. It hasn't been aproved yet
            0
        • What do you think about this stock after Oppenheimer Fall Healthcare of yesterday ?
          0
          • "Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy"... Pre Market +30-50%
            0
            • https://www.globenewswire.com/news-release/2019/12/02/1954700/0/en/Avadel-Pharmaceuticals-Announces-Key-Appointments-to-Leadership-Team-To-Support-Continued-Transformation-and-the-Advancement-of-FT218.html
              0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.